<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049851</url>
  </required_header>
  <id_info>
    <org_study_id>C18-57</org_study_id>
    <nct_id>NCT04049851</nct_id>
  </id_info>
  <brief_title>Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients</brief_title>
  <acronym>EOLoa</acronym>
  <official_title>Randomized Clinical Trial, Double-blind, Single-dose Drug and Escalating Infection Intensities, Evaluating the Safety and Efficacy of Moxidectin 2 mg, Ivermectin-controlled, in Loa Loa Microfilaremic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the safety and efficacy of Moxidectin 2 mg in patients with low&#xD;
      intensities of microfilariae of Loa loa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial will be randomized, double blind, and will compare Moxidectin to&#xD;
      ivermectin. This study will be conducted in Cameroon.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    transfer to another sponsor&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of severe adverse events post Moxidectin 2 mg</measure>
    <time_frame>1 week</time_frame>
    <description>Absence of severe adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events with Moxidectin 2 mg</measure>
    <time_frame>1 week</time_frame>
    <description>Proportion of adverse events during the first week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of reduction of the microfilarial densities of Loa loa : short term efficacy</measure>
    <time_frame>Day 7 and Day 15</time_frame>
    <description>Proportion of reduction of the microfilarial densities of Loa loa at Day 7 and Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of reduction of the microfilarial densities of Loa loa : long term efficacy</measure>
    <time_frame>Day 80, Day 180, and Year 1</time_frame>
    <description>Proportion of reduction of the microfilarial densities of Loa loa at Day 80, Day 180, and Day 365</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of individuals without microfilaria post Moxidectin 2 mg</measure>
    <time_frame>Day 7, Day 90, Day 180, and Year 1</time_frame>
    <description>Percentage of individuals without microfilariae of Loa loa at Day 7, Day 90, Day 180, and Day 365</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Onchocerciasis, Ocular</condition>
  <condition>Loiasis</condition>
  <arm_group>
    <arm_group_label>Moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxidectin 2 MG Oral Tablet</intervention_name>
    <description>One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.</description>
    <arm_group_label>Moxidectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 3Mg Tab</intervention_name>
    <description>3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.</description>
    <arm_group_label>Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.</description>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_label>Moxidectin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent written, signed (or with a cross) and dated&#xD;
&#xD;
          -  Men aged 18 to 65 included (women not included in the study)&#xD;
&#xD;
          -  Microfilarial density between 1 and 1,000 mf/mL&#xD;
&#xD;
          -  body weight ≥ 45 kg and less than 85 kg&#xD;
&#xD;
          -  Good general condition, as determined by the medical questionnaire and clinical&#xD;
             examination&#xD;
&#xD;
          -  Hematological parameters and adequate renal and hepatic functions, such as:&#xD;
&#xD;
               -  Leukocytes ≥ 2800 and ≤ 11300 cells / mL&#xD;
&#xD;
               -  Hemoglobin ≥ 11.0 g / dL&#xD;
&#xD;
               -  Platelets ≥ 130.000 / mm3&#xD;
&#xD;
               -  Creatine serum ≤ 1.25 upper limit of the laboratory&#xD;
&#xD;
               -  Total bilirubinemia ≤ 1.25 upper limit of the laboratory&#xD;
&#xD;
               -  ALAT ≤ 1.25 upper limit of the laboratory&#xD;
&#xD;
               -  Negative urinary strip: absence of leukocyturia, hematuria, and proteinuria&#xD;
                  (urine strip made a second time in case of positivity, for confirmation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any study other than purely observational, in the 4 weeks preceding&#xD;
             this study (determined by the theoretical date of administration of MOX-2 mg or IVM).&#xD;
&#xD;
          -  Person who has taken IVM in the last 6 months&#xD;
&#xD;
          -  Any vaccination in the 4 weeks preceding this study&#xD;
&#xD;
          -  Acute infection requiring a treatment in the 10 days preceding this study, determined&#xD;
             by the anamnesis during the medical interview (example: pulmonary infection, ENT,&#xD;
             digestive, cutaneous, with implementation of an antibiotic treatment or not)&#xD;
&#xD;
          -  Long-term antiretroviral therapy (protease inhibitor, non-nucleoside reverse&#xD;
             transcriptase inhibitor), or treatment with ampicillin or chloramphenicol within 10&#xD;
             days prior to administration of the test drug&#xD;
&#xD;
          -  History or presence of neurological (including epilepsy) or neuropsychiatric disease&#xD;
&#xD;
          -  Excessive consumption of alcohol or other drug abuse within 72 hours prior to the&#xD;
             administration of the test treatment determined by the medical history during the&#xD;
             medical interview.&#xD;
&#xD;
          -  Any condition, in the opinion of the investigator, which exposes the subject to an&#xD;
             undue risk&#xD;
&#xD;
          -  Subjects who donated blood in the 8 weeks prior to study entry, with a standard volume&#xD;
             (&gt; 500 mL)&#xD;
&#xD;
          -  Known intolerance to IVM, MOX or any of the excipients (including placebo)&#xD;
&#xD;
          -  During the clinical examination: symptoms, physical signs or biological constants&#xD;
             suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary,&#xD;
             cutaneous, immunodeficiency, psychiatric disorders and other abnormalities likely to&#xD;
             interfere with the interpretation results of the test. The doctor may then give a&#xD;
             favorable or unfavorable opinion for the inclusion of the participant&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre de recherche sur les filarioses et autres maladies tropicales (CRFilMT)</name>
      <address>
        <city>Yaoundé</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
    <mesh_term>Onchocerciasis, Ocular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Moxidectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

